Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT03242213 Recruiting - Clinical trials for Major Depressive Disorder

Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement

Start date: July 20, 2017
Phase: N/A
Study type: Interventional

The current randomized controlled trial is a pilot study that will assess the effectiveness and feasibility of a mobile phone application intervention. The objective is to determine whether the use of a mobile health application for patient self-management of depression improves patient-provider engagement for patients diagnosed with major depressive disorder.

NCT ID: NCT03237078 Not yet recruiting - Clinical trials for Major Depressive Disorder

Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Recent studies have suggested that gut-brain axis may be one of the mechanisms of major depression disorder (MDD). In animal studies, alteration of gut microbiota can affect animal's depression or anxiety-like behavior, brain neurochemistry and inflammation. In human studies, the composition of gut microbiota is different between patients with MDD and healthy controls. In addition, supplementation of probiotics can improve mood status in community and clinical participants. Inflammation is one of possible pathway to connect gut and brain. Gut permeability and inflammation level are higher in patients with MDD. Lactobacillus plantarum PS128 in one of bacteria extracted from traditional fermented food, Fu-Tsai. It can alleviate depressive-like behavior reduce inflammation level in maternal separation mice. This study is an 8-week open trial to investigate the effects of Lactobacillus plantarum PS128 on psychophysiology in patients with MDD and higher level of inflammation. This is a two-phase study. In the first phase, we will recruited patients fulfilling the following inclusion criteria: Age 20-65; fulfill Diagnostic and Statistical Manual of Mental Disorders fifth version (DSM-V) criteria of major depressive episode in recent 2 years; Psychotropics including antidepressants, antipsychotics and hypnotics have been kept unchanged for at least 3 months. The exclusion criteria are: comorbid with schizophrenia, bipolar disorder, or other substance use (except tobacco) disorder; having active suicidal or homicidal ideation; known allergy to probiotics; comorbid with hypertension, diabetes mellitus, irritable bowel syndrome, inflammatory bowl disease, liver cirrhosis, or autoimmune diseases; known active bacterial, fungal, or viral infections in one month; use of antibiotics, steroid, immunosuppressants, probiotics, or synbiotics in the month before collecting blood and fecal samples; pregnant or lactating women; who state to have dietary pattern changed or in diet within previous two months. Those hs-CRP > 3 mg/L in the first screen will be invited into the second phase intervention. In the second phase intervention, we will give eligible patients Lactobacillus plantarum PS128 for 8 weeks, and compare depression symptoms, gut microbiota, gut inflammation and permeability, and serum inflammation level before and after intervention.

NCT ID: NCT03230682 Recruiting - Clinical trials for Major Depressive Disorder

Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder

Start date: July 25, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Early improvemrnt, decreased 20% in the 17 items of Hamilton Depression Rating Scale (HAMD-17) at the second week of the treatment of major depression disorder (MDD), can arguably predict the remission at the 12th week. Our observation study including 80 MDD patients will access resting-state function MRI to finding factors which infuencing early improvemrnt, respone and remission of antidepressants.

NCT ID: NCT03228953 Recruiting - Clinical trials for Major Depressive Disorder

Pharmacogenomic Testing in Major Depressive Disorder

Start date: August 2017
Phase: N/A
Study type: Interventional

This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be randomly assigned to two groups: pharmacogenomic-guided therapy group (guided group) and treatment as usual group (TAU group). The primary hypothesis is the pharmacogenomic-guided treatment group will demonstrate significantly higher percent improvement in depression score compared to treatment-as-usual group.

NCT ID: NCT03222752 Recruiting - Clinical trials for Major Depressive Disorder

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

Start date: June 5, 2017
Phase: N/A
Study type: Interventional

Efficacy of Cranial Electrotherapy Stimulation (CES) for the treatment of Major Depressive Disorder

NCT ID: NCT03203954 Recruiting - Clinical trials for Major Depressive Disorder

Testing the Neuroscience of Guided Learning in Depression

Start date: May 1, 2016
Phase: N/A
Study type: Interventional

Major depression is a prevalent and impairing illness. To better understand the basic science and treatment of depression, the investigators study the behavioral and brain processes associated with learning in depression and how potential disruptions in learning may be repaired. Understanding different methods that change learning may lead to novel treatments that contribute to recovery in people with depression.

NCT ID: NCT03202095 Not yet recruiting - Clinical trials for Major Depressive Disorder

Creatine for Treatment of Depression Associated With Type 2 Diabetes

Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The investigators hypothesize that the administration of a widely available, naturally occurring dietary supplement, creatine monohydrate, will reduce the severity of depression in individuals with type 2 diabetes. The purpose of this study is to determine whether 12 weeks of creatine supplementation is an effective treatment for depression in individuals with type 2 diabetes.

NCT ID: NCT03193398 Recruiting - Clinical trials for Major Depressive Disorder

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

Start date: June 12, 2017
Phase: Phase 2
Study type: Interventional

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

NCT ID: NCT03191994 Recruiting - Clinical trials for Major Depressive Disorder

Impact of an Eight Week Exercise Intervention in Treating Major Depressive Disorder

Start date: January 2, 2014
Phase: N/A
Study type: Interventional

To investigate the impact of a structured eight week exercise intervention as an add-on therapy in treating Major Depressive Disorder. Using behavioural techniques and neuroimaging to measure changes in brain function following an exercise intervention in people with clinical depression. By correlating changes in the hippocampus with changes in HPA axis hormones, inflammatory cytokines and growth factors it is possible to determine which of the biochemical markers is most predictive of improved neural function.

NCT ID: NCT03188185 Recruiting - Clinical trials for Major Depressive Disorder

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.